Redwood Pharma AB (publ) to present at Stockholm Corporate Finance Life Science Seminar

Redwood Pharma AB (publ) will present at 8:00 on Wed. March 22, 2017 at Operaterassen,  Stockholm. To attend, please visit the online link below:

https://www.lyyti.fi/reg/Stockholm_Corporate_Finance_Life_Science_Seminarium_0041

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.com

About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel®, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).

For more information visit: www.redwoodpharma.com